Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme to present Keytruda data at GI Cancers Symposium

Merck Sharp and Dohme to present Keytruda data at GI Cancers Symposium

21st January 2016

Merck Sharp and Dohme will be sharing its latest Keytruda research insights at the Gastrointestinal (GI) Cancers Symposium, which takes place in San Francisco this week.

Commencing today (January 21st 2016) and running until January 23rd, the event gives Merck Sharp and Dohme the opportunity to present new and updated findings investigating the use of the anti-PD-1 therapy in multiple gastrointestinal cancers.

Updates include data on advanced oesophageal carcinoma and new preliminary phase II safety data in gastric cancer, with the Keytruda clinical programme currently including more than 30 tumour types across around 200 clinical trials.

Among these are seven registration-enabling studies in gastric, colorectal and oesophageal cancer, with further research assessing the drug's efficacy in the treatment of melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, Hodgkin lymphoma, multiple myeloma and breast cancer.

Dr Roger Dansey, senior vice-president and therapeutic area head for oncology late-stage development at Merck Research Laboratories, said: "Through our rapidly advancing clinical programme, we have seen promising results with Keytruda in several gastrointestinal cancers, and are hopeful about the potential of Keytruda for these patients."ADNFCR-8000103-ID-801810577-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.